US DSCSA vs EU FMD
Two serialization regimes fighting falsified medicines — different models.
What a comparison is not
A comparison is SPEQ’s reading of how two published documents differ. Neither is the right answer, it is not a determination of which applies to you, and neither is summarised in a way that replaces reading it.
The US Drug Supply Chain Security Act (DSCSA) and the EU Falsified Medicines Directive (FMD) both aim to keep falsified medicines out of the legitimate supply chain through serialization and verification. But they use different models: DSCSA builds an interoperable, electronic, package-level traceability system across trading partners, while the FMD uses an end-to-end verification model with a unique identifier checked against a central repository and an anti-tamper device.
| ASPECT | US DSCSA | EU FMD |
|---|---|---|
| Legal instrument | DSCSA (Title II of the DQSA, 2013) | Directive 2011/62/EU + Delegated Regulation (EU) 2016/161 |
| Model | Interoperable electronic package-level traceability (track-and-trace) | End-to-end verification against a central repository + tamper-evidence |
| Identifier | Product identifier (GTIN, serial, lot, expiry) — GS1 syntax | Unique identifier (product code, serial, batch, expiry) + anti-tampering device |
| Where verified | Along the chain; enhanced drug distribution security by Nov 2023 (with stabilization period) | Decommissioned at the point of dispense (pharmacy) |
| Repository | Distributed, trading-partner interoperable systems | Central EU hub + national medicines verification systems |
| Standards body | GS1 identifier syntax | GS1 identifier syntax (2D Data Matrix) |
Work to DSCSA for the US market — the model is interoperable, electronic, package-level tracing among authorised trading partners, with product-identifier verification and saleable-returns checks.
Work to EU FMD for the EU market — the model is a unique identifier verified against the EMVS repository and decommissioned at dispense, plus a physical anti-tampering device on the pack.
Same goal, different architecture: DSCSA is track-and-trace across trading partners; FMD is end-to-end verification against a central hub with decommissioning at the pharmacy. Both lean on GS1 for the identifier syntax, which is why a single 2D Data Matrix can carry the data for both — but the systems, verification points, and the FMD’s mandatory tamper-evident packaging are not interchangeable. Serialize once to GS1; implement the two verification models separately.
US DSCSA vs EU FMD: frequently asked questions
Common questions on how US DSCSA and EU FMD differ and when each applies.
Are DSCSA and FMD the same thing?
No. Both fight falsified medicines through serialization, but DSCSA (US) builds interoperable, electronic, package-level traceability among trading partners, while the FMD (EU) uses end-to-end verification against a central repository plus a physical anti-tamper device, with decommissioning at the point of dispense.
Can one 2D barcode serve both markets?
The identifier syntax is shared (both use GS1 in a 2D Data Matrix carrying product code, serial, batch, and expiry), so the data carrier can be common — but the verification systems, the repositories, and the FMD’s anti-tampering requirement differ, so compliance is implemented separately per market.
What is the EMVS?
The European Medicines Verification System — the central EU hub plus national medicines verification systems where unique identifiers are uploaded and verified, and where packs are decommissioned when dispensed under the FMD.
What changed with DSCSA in 2023?
November 2023 marked the move to enhanced drug distribution security — interoperable, electronic, package-level tracing — though the FDA provided a stabilization period to allow trading partners to reach full interoperability. Firms should follow current FDA guidance for exact timelines.